Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness. (Record no. 29362020)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02323 a2200637 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250518023050.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 202009s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1537-6591 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1093/cid/ciz100 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Gamiño-Arroyo, Ana E |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20200914 |
| 245 00 - TITLE STATEMENT | |
| Title | Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
| Date of publication, distribution, etc. | 11 2019 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1903-1911 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Adolescent |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Adult |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antiviral Agents |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Child |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Child, Preschool |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Double-Blind Method |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Hospitalization |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Kaplan-Meier Estimate |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Nitro Compounds |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Oseltamivir |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Severe Acute Respiratory Syndrome |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Thiazoles |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Treatment Outcome |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Young Adult |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Zanamivir |
| General subdivision | adverse effects |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Guerrero, M Lourdes |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | McCarthy, Sean |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ramírez-Venegas, Alejandra |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Llamosas-Gallardo, Beatriz |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Galindo-Fraga, Arturo |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Moreno-Espinosa, Sarbelio |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Roldán-Aragón, Yuri |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Araujo-Meléndez, Javier |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hunsberger, Sally |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ibarra-González, Violeta |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Martínez-López, Julia |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | García-Andrade, Luis A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kapushoc, Heather |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Holley, H Preston |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Smolskis, Mary C |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ruiz-Palacios, Guillermo M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Beigel, John H |
| 773 0# - HOST ITEM ENTRY | |
| Title | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
| Related parts | vol. 69 |
| -- | no. 11 |
| -- | p. 1903-1911 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1093/cid/ciz100">https://doi.org/10.1093/cid/ciz100</a> |
| Public note | Available from publisher's website |
No items available.